Treatment of canine leukocyte adhesion deficiency by foamy virus vectors expressing CD18 from a PGK promoter

Gene Therapy

Volumn 18, Issue 6, 2011, Pages 553-559

  Bauer, T R ^a   Olson, E M ^b   Huo, Y ^b,e   Tuschong, L M ^a   Allen, J M ^b,f   Li, Y ^b   Burkholder, T H ^c   Russell, D W ^b,d  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^e STANFORD UNIVERSITY   (United States)

^f Immune Design Corp   (United States)

Author keywords

canine; foamy virus; hematopoietic stem cell; immunodeficiency; retrovirus

Indexed keywords

CD18 ANTIGEN; CD34 ANTIGEN; ELONGATION FACTOR 1ALPHA; FOAMY VIRUS VECTOR; PHOSPHOGLYCERATE KINASE; UNCLASSIFIED DRUG; VIRUS VECTOR;

ANIMAL EXPERIMENT; ARTICLE; B LYMPHOCYTE; CANINE LEUKOCYTE ADHESION DEFICIENCY; DOG DISEASE; GENE ACTIVATION; GENE EXPRESSION; HEMATOPOIETIC STEM CELL; IN VITRO STUDY; LEUKOCYTE; LEUKOCYTE ADHESION DEFICIENCY; MONOCYTE; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; VIRAL GENE THERAPY;

ANIMALS; ANTIGENS, CD18; DOGS; GENE THERAPY; GENETIC VECTORS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; LEUKOCYTE-ADHESION DEFICIENCY SYNDROME; LEUKOCYTES; MODELS, ANIMAL; NEUTROPHILS; PHOSPHOGLYCERATE KINASE; PROMOTER REGIONS, GENETIC; SPUMAVIRUS;

CANIS FAMILIARIS; HUMAN SPUMARETROVIRUS; MURINAE;

EID: 79958288056     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2010.169     Document Type: Article

References (40)

1. Gaspar HB, Parsley KL, Howe S, King D, Gilmour KC, Sinclair J et al. Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector. Lancet 2004; 364: 2181-2187. (Pubitemid 40018447)
2. Cavazzana-Calvo M, Hacein-Bey S, de Saint Basile G, Gross F, Yvon E, Nusbaum P et al. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 2000; 288: 669-672. (Pubitemid 30241569)
3. Aiuti A, Slavin S, Aker M, Ficara F, Deola S, Mortellaro A et al. Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science 2002; 296: 2410-2413. (Pubitemid 34734219)
4. Cartier N, Hacein-Bey-Abina S, Bartholomae CC, Veres G, Schmidt M, Kutschera I et al. Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science 2009; 326: 818-823.
5. Ott MG, Schmidt M, Schwarzwaelder K, Stein S, Siler U, Koehl U et al. Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med 2006; 12: 401-409.
6. Howe SJ, Mansour MR, Schwarzwaelder K, Bartholomae C, Hubank M, Kempski H et al. Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J Clin Invest 2008; 118: 3143-3150.
7. Hacein-Bey-Abina S, Von Kalle C, Schmidt M, McCormack MP, Wulffraat N, Leboulch P et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 2003; 302: 415-419. (Pubitemid 37296260)
8. Wu X, Li Y, Crise B, Burgess SM. Transcription start regions in the human genome are favored targets for MLV integration. Science 2003; 300: 1749-1751. (Pubitemid 36712571)
9. Modlich U, Bohne J, Schmidt M, von Kalle C, Knoss S, Schambach A et al. Cell-culture assays reveal the importance of retroviral vector design for insertional genotoxicity. Blood 2006; 108: 2545-2553.
10. Zychlinski D, Schambach A, Modlich U, Maetzig T, Meyer J, Grassman E et al. Physiological promoters reduce the genotoxic risk of integrating gene vectors. Mol Therapy 2008; 16: 718-725. (Pubitemid 351426173)
11. Schroder AR, Shinn P, Chen H, Berry C, Ecker JR, Bushman F. HIV-1 integration in the human genome favors active genes and local hotspots. Cell 2002; 110: 521-529. (Pubitemid 35232295)
12. McBurney MW, Sutherland LC, Adra CN, Leclair B, Rudnicki MA, Jardine K. The mouse Pgk-1 gene promoter contains an upstream activator sequence. Nucleic Acids Res 1991; 19: 5755-5761. (Pubitemid 21912985)
13. Hendrie PC, Huo Y, Stolitenko RB, Russell DW. A rapid and quantitative assay for measuring neighboring gene activation by vector proviruses. Mol Therapy 2008; 16: 534-540. (Pubitemid 351314993)
14. Montini E, Cesana D, Schmidt M, Sanvito F, Ponzoni M, Bartholomae C et al. Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration. Nat Biotechnol 2006; 24: 687-696. (Pubitemid 43882120)
15. Montini E, Cesana D, Schmidt M, Sanvito F, Bartholomae CC, Ranzani M et al. The genotoxic potential of retroviral vectors is strongly modulated by vector design and integration site selection in a mouse model of HSC gene therapy. J Clin Invest 2009; 119: 964-975.
16. Falcone V, Schweizer M, Neumann-Haefelin D. Replication of primate foamy viruses in natural and experimental hosts. Curr Top Microbiol Immunol 2003; 277: 161-180. (Pubitemid 36612745)
17. Trobridge G, Josephson N, Vassilopoulos G, Mac J, Russell DW. Improved foamy virus vectors with minimal viral sequences. Mol Therapy 2002; 6: 321-328. (Pubitemid 36305333)
18. Heinkelein M, Dressler M, Jarmy G, Rammling M, Imrich H, Thurow J et al. Improved primate foamy virus vectors and packaging constructs. J Virol 2002; 76: 3774-3783. (Pubitemid 34250542)
19. Mergia A, Heinkelein M. Foamy virus vectors. Curr Top Microbiol Immunol 2003; 277: 131-159. (Pubitemid 36612744)
20. Josephson NC, Trobridge G, Russell DW. Transduction of long-term and mobilized peripheral blood-derived NOD/SCID repopulating cells by foamy virus vectors. Hum Gene Therapy 2004; 15: 87-92. (Pubitemid 38147191)
21. Josephson NC, Vassilopoulos G, Trobridge GD, Priestley GV, Wood BL, Papayannopoulou T et al. Transduction of human NOD/SCID-repopulating cells with both lymphoid and myeloid potential by foamy virus vectors. Proc Natl Acad Sci USA 2002; 99: 8295-8300. (Pubitemid 34651046)
22. Vassilopoulos G, Trobridge G, Josephson NC, Russell DW. Gene transfer into murine hematopoietic stem cells with helper-free foamy virus vectors. Blood 2001; 98: 604-609.
23. Kiem HP, Allen J, Trobridge G, Olson E, Keyser K, Peterson L et al. Foamy virusmediated gene transfer to canine repopulating cells. Blood 2007; 109: 65-70. (Pubitemid 46053045)
24. Leurs C, Jansen M, Pollok KE, Heinkelein M, Schmidt M, Wissler M et al. Comparison of three retroviral vector systems for transduction of nonobese diabetic/severe combined immunodeficiency mice repopulating human CD34(+) cord blood cells. Hum Gene Therapy 2003; 14: 509-519. (Pubitemid 36442706)
25. Trobridge GD, Allen JM, Peterson L, Ironside CG, Russell D, Kiem HP. Foamy and lentiviral vectors transduce canine long-term repopulating cells at similar efficiency. Hum Gene Therapy 2009; 20: 519-523.
26. Zucali JR, Ciccarone T, Kelley V, Park J, Johnson CM, Mergia A. Transduction of umbilical cord blood CD34+ NOD/SCID-repopulating cells by simian foamy virus type 1 (SFV-1) vector. Virology 2002; 302: 229-235. (Pubitemid 35373851)
27. Trobridge GD, Miller DG, Jacobs MA, Allen JM, Kiem HP, Kaul R et al. Foamy virus vector integration sites in normal human cells. Proc Natl Acad Sci USA 2006; 103: 1498-1503. (Pubitemid 43191194)
28. Bauer Jr TR, Allen JM, Hai M, Tuschong LM, Khan IF, Olson EM et al. Successful treatment of canine leukocyte adhesion deficiency by foamy virus vectors. Nat Med 2008; 14: 93-97.
29. Anderson DC, Smith CW. Leukocyte adhesion deficiencies. In: Scriver CR, Sly WS (eds). The Metabolic and Molecular Bases of Inherited Disease. McGraw-Hill: New York, NY, 2001, pp 4829-4856.
30. Kijas JM, Bauer Jr TR, Gafvert S, Marklund S, Trowald-Wigh G, Johannisson A et al. A missense mutation in the beta-2 integrin gene (ITGB2) causes canine leukocyte adhesion deficiency. Genomics 1999; 61: 101-107. (Pubitemid 29487626)
31. Gu YC, Bauer Jr TR, Ackermann MR, Smith CW, Kehrli Jr ME, Starost MF et al. The genetic immunodeficiency disease, leukocyte adhesion deficiency, in humans, dogs, cattle, and mice. Comp Med 2004; 54: 363-372. (Pubitemid 39096021)
32. Hawley RG, Lieu FH, Fong AZ, Hawley TS. Versatile retroviral vectors for potential use in gene therapy. Gene Therapy 1994; 1: 136-138.
33. Uetsuki T, Naito A, Nagata S, Kaziro Y. Isolation and characterization of the human chromosomal gene for polypeptide chain elongation factor-1 alpha. J Biol Chem1989; 264: 5791-5798. (Pubitemid 19098044)
34. Ye ZQ, Qiu P, Burkholder JK, Turner J, Culp J, Roberts T et al. Cytokine transgene expression and promoter usage in primary CD34+ cells using particle-mediated gene delivery. Hum Gene Therapy 1998; 9: 2197-2205. (Pubitemid 28498006)
35. Schambach A, Bohne J, Chandra S, Will E, Margison GP, Williams DA et al. Equal potency of gammaretroviral and lentiviral SIN vectors for expression of O6-methylguanine- DNA methyltransferase in hematopoietic cells. Mol Therapy 2006; 13: 391-400. (Pubitemid 43056905)
36. Sumiyoshi T, Holt NG, Hollis RP, Ge S, Cannon PM, Crooks GM et al. Stable transgene expression in primitive human CD34(+) hematopoietic stem/progenitor cells, using the sleeping beauty transposon system. Hum Gene Therapy 2009; 20: 1607-1626.
37. Gunji Y, Nakamura M, Hagiwara T, Hayakawa K, Matsushita H, Osawa H et al. Expression and function of adhesion molecules on human hematopoietic stem cells: CD34+ LFA-1- cells are more primitive than CD34+ LFA-1+ cells. Blood 1992; 80: 429-436.
38. Bauer Jr TR, Creevy KE, Gu YC, Tuschong LM, Donahue RE, Metzger ME et al. Very low levels of donor CD18+ neutrophils following allogeneic hematopoietic stem cell transplantation reverse the disease phenotype in canine leukocyte adhesion deficiency. Blood 2004; 103: 3582-3589. (Pubitemid 38525697)
39. Nelson EJ, Tuschong LM, Hunter MJ, Bauer Jr TR, Burkholder TH, Hickstein DD. Lentiviral vectors incorporating a human elongation factor 1alpha promoter for the treatment of canine leukocyte adhesion deficiency. Gene Therapy 2010; 17: 672-677.
40. Baum C, Kustikova O, Modlich U, Li Z, Fehse B. Mutagenesis and oncogenesis by chromosomal insertion of gene transfer vectors. Hum Gene Therapy 2006; 17: 253-263.